Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

Abstract

Extracellular signal-regulated kinase (ERK)1/2 signalling mediates communication between growth factor receptors and the cell nucleus and has been linked to several key events in the transformation process such as proliferation and invasion. We therefore sought to delineate the degree of phosphorylated ERK1/2 in breast cancer and potential links to upstream receptors such as VEGFR2, ErbB2, downstream targets, such as Ets-2, as well as clinico-pathological parameters, clinical outcome and response to tamoxifen. ERK1/2 phosphorylation was assessed by immunohistochemistry using a phospho-specific ERK1/2 antibody in three breast cancer cohorts including a total of 886 tumours arranged in tissue arrays. Cohort I consisted of 114 patients, cohort II of 248 postmenopausal patients randomized to either 2 years of tamoxifen or no adjuvant treatment and cohort III of 524 patients. Surprisingly, ERK1/2 phosphorylation correlated inversely with tumour size. Phosphorylated ERK1/2 was further associated with the presence of VEGFR2 (cohorts II and III) and the degree of phosphorylated Ets-2, indicating in vivo, a signalling cascade from VEGFR2 via ERK1/2 to Ets-2 phosphorylation. Interestingly, ERK1/2 phosphorylation correlated with better survival in untreated patients independently of lymph-node status and tumour size indicating that ERK1/2 signalling might be associated with a less aggressive phenotype. Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC . (2002). Clin. Cancer Res., 8, 1747–1753.

  • Bottazzi ME, Zhu X, Bohmer RM and Assoian RK . (1999). J. Cell Biol., 146, 1255–1264.

  • Catalano A, Caprari P, Rodilossi S, Betta P, Castellucci M, Casazza A, Tamagnone L and Procopio A . (2003). FASEB J., 18, 358–360.

  • Chen Q, Kinch M, Lin T, Burridge K and Juliano R . (1994). J. Biol. Chem., 269, 26602–26605.

  • Cobb MH and Goldsmith EJ . (1995). J. Biol. Chem., 270, 14843–14846.

  • Collaborative GEBCT . (1998). Lancet, 351, 1451–1467.

  • Cross MJ, Dixelius J, Matsumoto T and Claesson-Welsh L . (2003). Trends Biochem. Sci., 28, 488–494.

  • De Placido S, Carlomagno C, De Laurentiis M and Bianco AR . (1998). Breast Cancer Res. Treat., 52, 55–64.

  • Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, Nagamine Y, McMahon M, Hume DA and Ostrowski MC . (1998). Mol. Cell. Biol., 18, 5148–5156.

  • Gee JM, Robertson JF, Ellis IO and Nicholson RI . (2001). Int. J. Cancer, 95, 247–254.

  • Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J and Lannigan DA . (1998). Mol. Cell. Biol., 18, 1978–1984.

  • Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D and Chambon P . (1995). Science, 270, 1491–1494.

  • Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW and Thomas KA . (1999). J. Biol. Chem., 274, 6453–6460.

  • Kollermann J and Helpap B . (2001). Am. J. Clin. Pathol., 116, 115–121.

  • Lodén M, Nielsen N, Roos G, Emdin S and Landberg G . (1999). Oncogene, 19, 2557–2566.

  • Lodén M, Perris F, Nielsen N, Emdin S and Landberg G . (2003). Anticancer Res., 23, 2053–2061.

  • Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F and Eppenberger U . (2000). Int. J. Cancer, 89, 384–388.

  • Nielsen N, Emdin S, Cajander J and Landberg G . (1997). Oncogene, 14, 295–304.

  • Ohtani N, Zebeede Z, Hout T, JA S, Sugimoto M, Ohashi Y, Sharrocks A, Peters G and Hara E . (2001). Nature, 409, 1067–1070.

  • Roovers K and Assoian R . (2000). BioEssays, 22, 818–826.

  • Roovers K, Davey G, Zhu X, Bottazzi ME and Assoian RK . (1999). Mol. Biol. Cell, 10, 3197–3204.

  • Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE and Landberg G . (2003). Breast Cancer Res. Treat., 82, 147–154.

  • Sahl B, Marotta A, Matthewson C, Ahluwalia M, Flint J, Owen D and Pelech S . (1999). Anticancer Res., 19, 731–740.

  • Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng M-H and Yue W . (2002). J. Steroid Biochem. Mol. Biol., 80, 239–256.

  • Schaeffer HJ and Weber MJ . (1999). Mol. Cell. Biol., 19, 2435–2444.

  • Sewing A, Wiseman B, Lloyd A and Land H . (1997). Mol. Cell. Biol., 17, 5588–5597.

  • Sivaraman VS, Wang H-y, Nuovo GJ and Malbon CC . (1997). J. Clin. Invest., 99, 1478–1483.

  • Smith JL, Schaffner AE, Hofmeister JK, Hartman M, Wei G, Forsthoefel D, Hume DA and Ostrowski MC . (2000). Mol. Cell. Biol., 20, 8026–8034.

  • Stendahl M, Kronblad AA, Ryden L, Emdin S, Bengtsson NO and Landberg G . (2004). Br. J. Cancer, 90, 1942–1948.

  • Takahashi T and Shibuya M . (1997). Oncogene, 14, 2079–2089.

  • Takahashi T, Ueno H and Shibuya M . (1999). Oncogene, 18, 2221–2230.

  • Takahashi T, Yamaguchi S, Chida K and Shibuya M . (2001). EMBO J., 20, 2768–2778.

  • Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD and Ellis LM . (1996). Clin. Cancer Res., 2, 1679–1684.

  • von Marschall Z, Cramer T, Hocker M, Burde R, Plath T, Schirner M, Heidenreich R, Breier G, Riecken EO, Wiedenmann B and Rosewicz S . (2000). Gastroenterology, 119, 1358–1372.

  • Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S and Fujinaga K . (1998). Int. J. Cancer, 77, 128–137.

  • Weber J, Raben D, Phillips P and Baldassare J . (1997). Biochem. J., 15, 61–68.

  • Wetzker R and Böhmer F . (2003). Nat. Rev. Mol. Cell. Biol., 4, 651–657.

  • Yang B, Hauser C, Henkel G, Colman M, Van Beveren C, Stacey K, Hume D, Maki R and Ostrowski M . (1996). Mol. Cell. Biol., 16, 538–547.

Download references

Acknowledgements

The authors are grateful for excellent technical assistance from Ms Elise Nilsson. This study was supported by grants from the Swedish Cancer Society, Lund University Research Funds, Malmö University Hospital Research and Cancer Funds, Gunnar, Arvid and Elisabeth Nilssons Cancer Foundation, Per-Erich and Ulla Schybergs Foundation and the Swegene/Wallenberg Consortium North (WCN).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Svensson, S., Jirström, K., Rydén, L. et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24, 4370–4379 (2005). https://doi.org/10.1038/sj.onc.1208626

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208626

Keywords

This article is cited by

Search

Quick links